Market Access BIO-Europe Spring 2026: In conversation with Marjorie Sidhou... Marjorie Sidhoum, vice president of business development & corporate communication at Kainova Therapeutics, discusses their immuno-oncology pipeline.
Market Access In DTC's watershed moment, trust and partnership are key More and more pharma companies are turning to direct-to-patient access models. But the consensus at Reuters Pharma USA is that they can't do it alone.
Market Access BIO-Europe Spring, Portugal: Propelling new wave innovation BIO-Europe Spring arrived in Lisbon, Portugal yesterday, running from 23rd to 25th March.
Market Access Is AI the missing link in fixing MLR – or the reason it brea... Somewhere in a shared drive at a mid-size pharma company, there is a folder labelled “Q3 Messaging FINAL v3 (2).” Inside it are three Word documents with tracked changes from four people, n
Market Access FTC leader: "We're up to the challenge" of coming merger boo... At Reuters Pharma USA, the FTC's Daniel Guarnera warned that healthcare is a major priority and they're ready to move against anticompetitive deals.
Market Access JPM 2026: What it revealed about biotech’s new reality JPM 2026 signalled genuine recovery – but not the kind the industry has historically celebrated.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.